Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Expected outcomes of therapy

11 evidence topics · 9 sources

Summary
  • Benefit per unit of blood pressure reduction: An individual participant-level meta-analysis of 48 trials found that each 5 mm Hg reduction in systolic blood pressure lowered the risk of major cardiovascular events by about 10%, with reductions of 13% for stroke, 13% for heart failure, 8% for ischemic heart disease, and 5% for cardiovascular death, irrespective of prior cardiovascular disease. A meta-analysis of 123 studies (613,815 participants) found that each 10 mm Hg reduction lowered major cardiovascular events (relative risk 0.80), coronary heart disease (0.83), stroke (0.73), heart failure (0.72), and all-cause mortality (0.87), with no significant effect on renal failure. FDA guidance attributes these benefits largely to the decrease in blood pressure itself across drug classes.
  • Lorundrostat: In Launch-HTN, lorundrostat 50 mg lowered office systolic blood pressure by 9.1 mm Hg more than placebo at week 6. No trial of lorundrostat or baxdrostat reporting cardiovascular, kidney, or mortality outcomes was identified; the placebo-controlled Launch-HTN comparison lasted 12 weeks.
  • Blood pressure as a surrogate: ICER states that blood pressure is a surrogate marker, that not all blood pressure drugs have the same effect on major adverse cardiovascular events and their effects on mortality are inconsistent, and that longer-term data are needed to determine the effect of aldosterone synthase inhibitors on patient-important outcomes. A review of FDA surrogate endpoints found 10 meta-analyses with inconsistent evidence on the strength of association between blood pressure reductions and cardiovascular outcomes and all-cause mortality. The Explore-OSA investigators state that a longer-term cardiovascular outcomes trial of lorundrostat should be considered.